After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring
Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.
We haven't written up this one. MarketWatch Top has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
